S&P, Nasdaq futures higher; U.S. jobs report ahead - what’s moving markets
Investing.com - Goldman Sachs has reiterated its Conviction Buy rating on AstraZeneca (NASDAQ:AZN) (AZN:LN) following the presentation of Phase 3 trial data for baxdrostat at ESC 2025.
The Phase 3 BaxHTN trial showed that baxdrostat demonstrated dose-dependent placebo-adjusted reductions in seated systolic blood pressure (SBP) at Week 12. The 2mg dose achieved a 9.8mmHg reduction while the 1mg dose showed an 8.7mmHg reduction without dose modification.
In an exploratory analysis, the 2mg dose demonstrated placebo-adjusted reductions of 16.9mmHg in ambulatory 24-hour SBP and 11.7mmHg in night-time SBP. These effects were attributed to the drug’s long half-life of 26 to 31 hours.
Safety data revealed confirmed moderate to severe hyperkalemia rates of 1.1% for both the 2mg and 1mg doses, compared to 0% with placebo. Discontinuation due to adverse events occurred at rates of 4.5% for the 2mg dose and 2.7% for the 1mg dose, versus 1.9% with placebo.
According to management statements during the conference call, no clinically meaningful drug-drug interactions were associated with baxdrostat, an important finding for the treatment’s potential clinical application.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.